|
|
|
| Correlation of serum FAI with AMH and IR in patients with polycystic ovary syndrome |
| SHEN Yong-hai, SHI Xin-yan, QIU Yuan, WANG Zhi-yi, CHEN Zhong-bao
|
| Clinical laboratory,Hangzhou obstetrics and Gynecology Hospital,Hangzhou,Zhejiang 310008,China |
|
|
|
|
Abstract Objective To explore the correlation of serum free androgen index（FAI）with anti-Mullerian hormone（AMH）and insulin resistance（IR）in patients with polycystic ovary syndrome（PCOS）. Methods We enrolled totally 113 untreated PCOS patients and divided them into two groups according to Homeostasis model assessment of insulin resistance（HOMA-IR）：59 cases in the non-insulin resistance（PCOS-NIR）group and 54 cases in the insulin resistance（PCOS-IR）group. Then we chose another 55 healthy women at the childbearing age as the control group. AMH,follicle-stimulating hormone（FSH）,luteinizing hormone（LH）,testosterone（T）,sex hormone binding globulin（SHBG）,Dehydroepiandrosterone sulfate（DHEAS）and insulin（INS）were detected in the three groups,and the correlation of FAI with AMH and IR were analyzed. Results The AMH,LH,LH/FSH,T,FAI levels of PCOS-NIR group and PCOS-IR group were higher than that of control group（P<0.05）. The BMI,DHEAS,INS and HOMA-IR levels of PCOS-IR group were higher than that of PCOS-NIR group（P<0.05）;the SHBG level of PCDS-IR group was lower than that of PCOS-NIR group（P<0.05） . The Pearson correlation analysis suggested that FAI had a negative correlation with SHBG and a positive correlation with AMH,LH,LH/FSH and DHEAS（P<0.05）. Conclusion The level of serum FAI in patients with PCOS significantly increased,which correlates closely with IR and the level of AMH. This study can provide a new reference for the clinical diagnosis of PCOS.
|
|
Received: 29 January 2018
Revised: 02 March 2018
Published: 22 May 2018
|
|
|
|
|
|
[1] LUNGU A O,ZADEH E S,GOODLING A,et al.Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome[J]. J Clin Endocrinol Metab,2012,97(2):563-567.
[2] YILDIZ B O,BOZDAG G,YAPICI Z,et al.Prevalence,phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria[J]. Hum Reprod,2012,27(10):3067-3073.
[3] QIAO J.Pay more attention to ethnic differences in polycystic ovary syndrome phenotypic expression[J]. Chin Med J,2013,126(11):2003-2006.
[4] 陈洁,陈晨. AMH在多囊卵巢综合征中的研究进展[J].生殖医学杂志,2017,26(5):490-493.
[5] 时照明,吴道爱,张士荣,等. 多囊卵巢综合征患者肥胖、高胰岛素和高雄激素血症的相关性研究[J]. 中国糖尿病杂志,2012,20(7):489-492.
[6] 彭璇,李霞,辜敏. 多囊卵巢综合征患者血清抗苗勒氏管激素与游离睾酮指数的相关性研究[J]. 中国妇幼保健,2015,30(34):5960-5962.
[7] 刘隆. 多囊卵巢综合征的临床进展——对2015年AACE/ACE多囊卵巢综合征临床实践指导的解读[J]. 内科急危重症杂志,2017,23(4):269-271.
[8] 王丽萍,方春霞,蔡文伟,等. PCOS患者AMH水平与肥胖、睾酮水平、胰岛素抵抗的相关性分析[J]. 浙江医学,2016,38(16):1354-1357.
[9] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to Polycystic ovary syndrome society[J]. Fertil Steril,2004,81(1):19-25.
[10] CHEN M J,YANG W S,YANG J H,et al.Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome[J]. Hypertension,2007,49(6):1442-1447.
[11] 赵丽,吕时铭.抗苗勒管激素的研究与应用进展[J].中华检验医学杂志,2014,37(7):509-512.
[12] LIE F S,VISSER J A,WELT C K,et al.Serum anti-Müllerian hormone levels in healthy females:a nomogram ranging from infancy to adulthood[J]. J Clin Endocrinol Metab,2012,97(12):4650-4655.
[13] 罗超,陈少科. 抗苗勒管激素检测在儿科中的应用[J]. 实用医学杂志,2016,32(9):1381-1383.
[14] MORCIANO A,ROMANI F,SAGNELLA F,et al.Assessment of insulin resistance in lean women with polycystic ovary syndrome[J]. Fertil Steril,2014,102(1):250-256.
[15] CHEN M J,YANG W S,CHEN C L,et al.The relationship between anti-Müllerian hormone,androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome[J]. Hum Reprod,2008,23(4):952-957.
[16] VOSNAKIS C,GEORGOPOULOS N A,ROUSSO D,et al.Diet,physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH)levels in women with polycystic ovary syndrome (PCOS)[J]. Gynecol Endocrinol,2013,29(3):242-245.
[17] LOBO R A .What are the key features of importance in polycystic ovary syndrome?[J]. Fertil Steril,2003,80(2):259-261.
[18] PIOUKA A,FARMAKIOTIS D,KATSIKIS I,et al.Anti- Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity:relationship with increased luteinizing hormone levels[J]. Am J Physiol Endocrinol Metab,2009,296(2):238-243.
[19] EHRMANN D A.Polycystic ovary syndrome[J]. N Engl J Med,2005,352(12):1223-1236.
[20] SIRMANS S M,PATE K A.Epidemiology,diagnosis,and management of polycystic ovary syndrome[J]. Clin Epidemiology,2013,18(6):1-13. |
|
|
|
